Safety and immune response to a challenge dose of hepatitis B vaccine in healthy children primed 10 years earlier with hexavalent vaccines in a 3, 5, 11-month schedule : an open-label, controlled, multicentre trial in Italy
Articolo
Data di Pubblicazione:
2017
Citazione:
Safety and immune response to a challenge dose of hepatitis B vaccine in healthy children primed 10 years earlier with hexavalent vaccines in a 3, 5, 11-month schedule : an open-label, controlled, multicentre trial in Italy / A. Zanetti, M.G. Desole, L. Romanò, A. D'Alessandro, M. Conversano, G. Ferrera, M.G. Panico, A. Tomasi, G. Zoppi, M. Zuliani, S. Thomas, B. Soubeyrand, C. Eymin, S. Lockhart. - In: VACCINE. - ISSN 0264-410X. - 35:32(2017 Jul 13), pp. 4034-4040. [10.1016/j.vaccine.2017.05.047]
Abstract:
BACKGROUND AND AIMS:
The strategy of vaccinating infants to prevent hepatitis B virus infection in adolescence or adulthood requires durable immunity. This study investigated responses to a challenge dose of monovalent hepatitis B vaccine in children primed with three doses of either Hexavac® or Infanrix hexa® 10years earlier during infancy.
METHODS:
This open-label, controlled, multicentre study conducted in Italy, enrolled 751 healthy pre-adolescents (aged 11-13years) who were given either Hexavac (n=409) or Infanrix hexa (n=342) at 3, 5 and 11months of life. All participants received a challenge dose of a monovalent hepatitis B vaccine (HBVaxPro® 5µg). The concentrations of antibodies to hepatitis B surface antigen (anti-HBs) were measured before and 1month after the challenge dose. The analysis was descriptive and no formal hypothesis was tested.
RESULTS:
One month post-challenge, 331 participants in the Hexavac cohort [83.6%, 95% CI: 79.6; 87.1] and 324 in the Infanrix hexa cohort [96.4%, 95% CI: 93.8; 98.1] had anti-HBs concentrations ≥10mIU/mL. Before the challenge dose, an anti-HBs concentration of ≥10mIU/mL was found in 94 children in the Hexavac cohort [23.9%, 95% CI: 19.7; 28.4] and in 232 children in the Infanrix hexa cohort [69%, 95% CI: 63.8; 74.0]. Among children with a pre-challenge anti-HBs concentration of <10mIU/mL, 236 [78.7%, 95% CI: 73.6; 83.2] in the Hexavac cohort and 92 [88.5%, 95% CI: 80.7; 93.9] in the Infanrix hexa cohort achieved protective anti-HBs antibody concentrations. No evidence of active hepatitis B disease was observed in either group, and the HBVaxPro challenge dose was well tolerated.
CONCLUSIONS:
These data confirm that immune memory persists in a high percentage of children (>80%) at least 10years after a two-dose primary and booster vaccination schedule with a hexavalent vaccine (Hexavac or Infanrix hexa).
TRIAL REGISTRATION:
EudraCT Number: 2013-001602-28; clinicaltrials.gov: NCT02012998.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Challenge dose; Hepatitis B; Hexavalent vaccine; Immune memory; Vaccinated children
Elenco autori:
A. Zanetti, M.G. Desole, L. Romanò, A. D'Alessandro, M. Conversano, G. Ferrera, M.G. Panico, A. Tomasi, G. Zoppi, M. Zuliani, S. Thomas, B. Soubeyrand, C. Eymin, S. Lockhart
Link alla scheda completa: